Background Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody against amyloid β. ARIA include MRI signal abnormalities suggestive of vasogenic oedema and sulcal eff usions (ARIA-E) and microhaemorrhages and haemosiderin deposits (ARIA-H). Our aim was to investigate the incidence of ARIA during treatment with bapineuzumab, and evaluate associated risk factors.
Introduction
Numerous clinical trials are investigating active or passive immunotherapeutic approaches to reduce cerebral amyloid-β burden as treatments for Alzheimer's disease. [1] [2] [3] [4] Several of these studies have reported treatment-related abnormalities in brain images, but the pathophysiology underlying these changes is uncertain. [1] [2] [3] [4] Furthermore, because these imaging abnormalities can be clinically silent, their exact incidence and the spectrum of associated clinical features is unclear.
Imaging abnormalities associated with immunotherapy were fi rst noted in a phase 1 study of bapineuzumab, 3 a humanised monoclonal antibody against β amyloid, and then in phase 2 bapineuzumab studies. 1, 2 The MRI abnormalities, seen in T2*-weighted, fl uid-attenuated inversion recovery (FLAIR) sequences, were initially referred to as vasogenic oedema. 4 As additional cases were identifi ed in sub sequent trials, it became clear that a spectrum of imaging alterations associated with amyloid-modifying treatments existed. An expert workgroup has suggested the use of an umbrella termamyloid-related imaging abnormalities (ARIA) 5 -which includes FLAIR signal abnormalities thought to represent parenchymal vasogenic oedema and sulcal eff usions (ARIA-E), as well as abnormalities detectable on T2*-weighted gradient echo sequences that are thought to represent microhaemorrhages and haemosiderosis (ARIA-H).
This report focuses on incident ARIA in the setting of clinical trials of bapineuzumab treatment; however, the fi ndings could also have implications for other antiamyloid therapies. Because the original protocols for these trials included only MRI readings done by local radiologists, who might have had limited previous experience with ARIA, some cases of ARIA might have been missed. Therefore, we did a systematic, central review of all MRI data from these studies to assess the incidence of ARIA during bapineuzumab treatment, and their associated risk factors and clinical characteristics.
Methods

Participants and procedures
We reviewed all MRI scans performed before Feb 1, 2009 , in two phase 2 bapineuzumab clinical trials (study 201 and study 202 1, 2 ) and the associated ongoing open-label extension study (study 251; registered at ClinicalTrials. gov, number NCT00606476). We used several procedures to ensure maximum sensitivity for ARIA detection. Two neuroradiologists (DT and a contracted reader), who had full access to all MRI scans at all timepoints, retrospectively reviewed the scans for each participant; they were masked to the participant's assigned therapy, APOE ε4 genotype, medical history, and demographics. The scans were fi rst read independently by each reader, then any diff erences between readings were discussed and resolved by consensus between the two readers.
Studies 201 and 202 were multicentre, double-blinded, randomised, placebo-controlled, ascending-dose cohort trials. 1, 2 Each study lasted for 18 months and included six infusions, 13 weeks apart. Study 251 is an ongoing extension study into which eligible patients from study 201 were recruited (webappendix). Patients in study 251 who had previously received bapineuzumab in study 201 were assigned to receive the same dose of bapineuzumab (n=80). Each dose cohort in study 201 had both actively treated and placebo treated patients; in the open-label study the patients who had previously received placebo received the dose of bapineuzumab associated with the dose cohort to which they were originally assigned in study 201 (n=79). No participants from study 202 were enrolled in study 251. MRI scans were done before the fi rst infusion of study drug or placebo and 6 weeks after each subsequent infusion in all studies.
The bapineuzumab phase 2 trials were approved by the local institutional review board at each site, and written informed consent was obtained from each patient (or legally authorised representative). All patients provided consent at entry into the phase 2 studies for the sponsor to access their study data and to do analyses based on these data.
Patients were classifi ed as having incident ARIA-E if they developed new parenchymal or sulcal hyperintensities on FLAIR MRI, consistent with extravascular fl uid, in the absence of other pathologies. Parenchymal hyper intensities were recorded as present or absent in the posterior fossa and in the left and right side in each of fi ve regions (frontal, temporal, parietal, occipital, and basal ganglia); we also assessed the overall presence or 
Figure 1: Flow chart of patients included in risk analyses
The shaded boxes show the patients who were treated with bapineuzumab and whose MRI scans were reviewed in this study. *ARIA-E were detected in one patient receiving placebo. †ARIA-E were detected in one patient who had metastatic lung cancer, and was not included in the risk factor analyses; the patient was censored at the time of ARIA-E detection. ARIA-E=amyloid-related imaging abnormalities thought to comprise parenchymal vasogenic oedema and sulcal eff usions.
See Online for appendix absence of sulcal hyperintensities. The total number of regions with ARIA-E was calculated. ARIA-H were also noted as present or absent in the same regions in the T2* images. White matter hyper intensities were classifi ed into four categories, according to an adapted four point scale:
6 0 (none), 1 (focal lesions), 2 (beginning of confl uent lesions), and 3 (diff use involvement). For the risk analyses, the white matter hyperintensities classifi ed in categories 0 and 1 were combined, as were those in categories 2 and 3, to test whether high-grade white matter hyperintensity (ie, more severe vascular pathology 7 ) was associated with ARIA-E. The risk analyses included data from patients with Alzheimer's disease treated with bapineuzumab in studies 201, 202, or 251 who had a post-infusion FLAIR MRI scan and no other diagnosed conditions deemed to be responsible for the imaging abnormalities. We focused on the risk factor analyses for ARIA-E; risk analyses for ARIA-H independent of ARIA-E are underway and we plan to report the fi ndings separately. Bapineuzumab dose was defi ned as the highest dose received. Patients with ARIA-E were classifi ed on the basis of whether ARIA was fi rst identifi ed during studies 201, 202, or 251, or during our MRI review, and as either symptomatic or asymptomatic. A patient was considered symptomatic if one or more symptoms were reported as related or possibly related to study drug in the ARIA safety report by the study investigator.
Statistical analysis
We used Kaplan-Meier analysis to examine the distribution of incident ARIA-E from start of treatment in the diff erent groups and Cox proportional hazards models to analyse risk factors. We used SAS (version 9.1) for all statistical analyses. We assessed the proportional hazards assumption by examining log versus negative log plots; no violations occurred. p value signifi cance thresholds were neither pre-specifi ed nor adjusted for multiplicity.
Role of the funding source
Employees of both sponsors (Janssen Alzheimer Immunotherapy Research and Development, and Pfi zer) were involved in the study design, data collection, data analysis, and data interpretation, and the writing and submission of the report. All authors had full access to the study data and shared responsibility for submitting the manuscript for publication.
Results
We reviewed 2572 MRI scans from 262 participants in studies 201, 202, or 251. Of these patients, 223 were ultimately treated with bapineuzumab and 39 were treated with placebo only (fi gure 1). Two patients (0·8% of all study participants) had ARIA-E that was present on screening MRI, both of whom were sub sequently treated with bapineuzumab and excluded from our analysis. An additional ARIA-E case was detected in the central review of the 118 patients treated with placebo.
11 patients treated with bapineuzumab were excluded from our study because they did not have a post-infusion FLAIR MRI. Thus, 210 participants were included in the analysis of risk factors associated with bapineuzumab treatment. One patient identifi ed during our MRI review as possibly having ARIA-E had been diagnosed by the local site investigator during the study as having brain metastases due to lung cancer, and hence considered to have imaging abnormalities not associated with bapineuzumab.
The inter-reader κ was 0·76, with 94% agreement between neuroradiologists about the presence or absence of ARIA-E within individual patients. ARIA-E were observed in 36 of 210 (17%) patients treated with bapineuzumab. Figure 2 shows the range of ARIA detected in this study. ARIA-E manifested as an increased signal on FLAIR MRI sequences in the white or grey matter parenchyma or within sulcal spaces, whereas ARIA-H were detected on T2*-weighted gradient echo sequences. The baseline prevalence of micro haemorrhage or haemosiderosis (ARIA-H) was 9·2% (19 of 207 participants; table 1). Incident ARIA-H was observed in 17 of 36 (47·2%) of the ARIA-E cases, and in seven of 177 (4·0%) patients without ARIA-E. Of the 17 patients with ARIA-E and incident ARIA-H, 14 had ARIA-H noted on the scan immediately before (n=2), coincident with (n=6), or immediately after (n=6) the scan in which ARIA-E was fi rst noted. Eight of these 14 patients had ARIA-H in the same region as ARIA-E. Table 1 presents fi ndings from the risk factor analysis. Baseline characteristics were much the same for patients with and without ARIA-E. The incidence of ARIA-E increased with bapineuzumab dose and frequency of APOE ε4 alleles. Table 2 shows proportional hazards models predictive of ARIA-E. The hazard ratios exceeded 3·0 for the two highest doses of bapineuzumab, when compared with the lowest dose. The hazard ratios were about three-times higher in APOE ε4 heterozygous carriers and seven-times higher in APOE ε4 homozygous carriers than in APOE ε4 non-carriers. The hazard ratio did not increase signifi cantly for those patients with small haemosiderin deposits or white matter hyperintensities on baseline MRI scans. When age, sex, baseline mini-mental state examination score, Hamilton depression rating scale score, Rosen-modifi ed Hachinski score, history of cerebro vascular disease, and hypertension were included in the analysis, they were not predictive of ARIA-E. Figure 3 shows the fi ndings from the Kaplan-Meier analysis by dose, APOE ε4 allele frequency, and the presence of small haemosiderin deposits at baseline. A dose-related increase in ARIA-E risk occurred for the 2 mg/kg dose (fi gure 3A), particularly after the fi rst infusion. For carriers of APOE ε4 alleles (fi gure 3B), the analysis showed a clear early diff erence in risk of ARIA-E that persisted with continued follow-up. The mean number of infusions before detection of ARIA-E was 2·4 (SD 1·7; range 1-7). Most ARIA-E cases (25 of 36; 69%) were identifi ed after the fi rst or second infusion. ARIA-E was not observed more than 2 years after the fi rst exposure to bapineuzumab. The median duration of ARIA-E for the 31 of 36 patients whose ARIA-E were resolved on follow-up scans was 113 days (IQR 61-182). Eight patients with ARIA-E identifi ed during the trial received a lower dose after ARIA-E resolved; ARIA-E recurred in one patient, who remained asymptomatic.
Eight of the 36 patients with ARIA-E had adverse events that were considered by the site investigator as related or possibly related to the study drug. The categories for these events were general (n=7, with headache in four), neurological (n=16, with confusion in fi ve), psychiatric (n=3), and gastrointestinal (n=3; webappendix). Of the eight symptomatic patients, seven were APOE ε4 carriers (fi ve homozygous and two heterozygous). Six of the eight symptomatic patients had received a 2 mg/kg dose (n=4) or 1 mg/kg dose (n=2). In all eight cases bapineuzumab was discontinued, and a follow-up MRI scan showed resolu tion of ARIA-E. One symptomatic patient in study 251 developed a left frontal stroke temporally associated with ARIA-E, but did not have focal symptoms clearly related to the location of either the stroke or the ARIA-E. 8 Although the ARIA-E resolved, the patient eventually died about 8 weeks later because of complications related to the stroke. Seven patients had ARIA-H without ARIA-E; none of these cases manifested clinical symptoms.
15 patients were identifi ed as having ARIA-E only during the MRI re-read. All were asymptomatic and had fewer brain regions involved (mean 1·3, SD 0·5) than patients identifi ed during the clinical studies (mean 2·6, 2·4; p=0·0193). 13 of these 15 received additional infusions of bapineuzumab-with doses ranging from 0·15 mg/kg to 2·0 mg/kg for up to 2 years-after ARIA-E fi rst appeared because the ARIA were not detected during the trial. All of these patients remained asymptomatic. In two of these 13 patients, ARIA-E recurred with additional infusions, but the patients were still asymptomatic.
CSF was collected from eight of 36 patients with ARIA. Five had a normal CSF profi le and three had high protein concentrations (259, 264, and 337 mg/dL) and red cell counts (360, 1280, and 108 cells per mm³). Two patients had increased white cell concentrations (8 and 19 cells per mm³), both of whom were symptomatic and APOE ε4 carriers. Figure 4 shows scans from a patient treated with bapineuzumab (2 mg/kg dose) who developed ARIA in study 202. This patient had ¹¹C Pittsburgh compound B (¹¹C PiB) PET amyloid imaging before and after ARIA. Baseline retention of ¹¹C PiB was increased (consistent with high fi brillar amyloid β burden) in several regions in which ARIA-E and ARIA-H sub sequently developed. Retention of ¹¹C PiB was reduced in these regions at the follow-up scan after ARIA-E had resolved.
Discussion
In this retrospective assessment of the incidence of ARIA in bapineuzumab-treated patients from two An increased risk of ARIA-E after the fi rst two infusions is shown on the basis of MRI readings done at 6 and 19 weeks after baseline in patients treated with the highest dose of bapineuzumab (2 mg/kg) and in APOE ε4 homozygotes. The presence of small haemosiderin deposits at baseline did not increase risk. ARIA-E=amyloid-related imaging abnormalities thought to be parenchymal vasogenic oedema and sulcal eff usions. sHD=small haemosiderin deposits.
phase 2 studies and an open-label study, ARIA was detected in 36 of 210 (17%) patients treated with bapineuzumab. Most cases were clinically silent. Roughly 40% of ARIA cases were fi rst detected in this retrospective review, all of whom were asymptomatic and continued to be treated while having ARIA-E. In some patients, ARIA recurred, but they remained asymptomatic. These newly identifi ed ARIA-E cases appeared to have milder FLAIR signal changes and fewer involved brain regions than did originally identifi ed ARIA-E cases. When the phase 2 studies started, little was known about the range of ARIA changes on MRI. With greater awareness of these abnormalities, it seems likely that local radiologists will miss fewer ARIA cases in the future. The mechanisms that cause ARIA need to be fully elucidated, but the risk factors identifi ed in this study, as well as data from animal models, suggest potential hypotheses (fi gure 5). The risk analyses provide quantitative evidence for increased risk of ARIA-E with increasing APOE ε4 allele frequency, which supports a preliminary report suggesting that the risk of ARIA-E is increased in APOE ε4 carriers.
1 APOE ε4 has been linked to development of cerebral amyloid angiopathy in transgenic mice. 9, 10 Post-mortem studies in people indicate that APOE ε4 is a risk factor for cerebral amyloid angiopathy [11] [12] [13] and spon taneous ARIA-E-like abnormalities have been reported in patients with cerebral amyloid angiopathy. 14, 15 APOE ε4 carrier status is also a risk factor for microhaemorrhage in the general population 16, 17 and in patients in memory clinics. 11, 18, 19 Too few ARIA-E cases occurred to fully test an interaction between APOE ε4 allele frequency and bapineuzumab dose, although that seven of eight symptomatic cases were APOE ε4 carriers and six of eight were treated with the two highest doses is suggestive of a potential relation that should be fully explored in larger studies. Together with the risk factor analyses, these fi ndings suggest that it might be possible to reduce bapineuzumab-related ARIA-E and associated symptoms by careful dosing, with attention to APOE ε4 status.
The presence of baseline ARIA-H was not found to be a signifi cant risk factor for ARIA-E in our study. However, patients with baseline microhaemorrhages were excluded from participation in study 251 because of concern that baseline microhaemorrhages could represent greater cerebral amyloid angiopathy and ARIA-E. About half of the patients treated with bapineuzumab who developed ARIA-E also developed ARIA-H, with most of these patients having evidence of temporal and spatial cooccurrence. These fi ndings suggest that ARIA-E and ARIA-H are related, perhaps both linked to increases in vascular permeability. 5 Dependent on the location (intraparenchymal or meningeal) of the vessel, the leakage of proteinaceous fl uid could cause an increased signal in FLAIR images (ARIA-E) in the brain parenchyma (vasogenic oedema) and leptomeningeal spaces (sulcal eff usions), whereas leakage of red cells would result in ARIA-H, seen on T2*-weighted gradient echo MRI as cerebral micro haemorrhages and haemo siderosis. 5 The increased risk of ARIA associated with high doses of bapineuzumab (as well as the PET amyloid imaging fi ndings from the patient for whom the ¹¹C PiB data were available), also suggests a potential relation between ARIA and amyloid clearance. The reduction of ¹¹C PiB retention, presumably a result of clearance of fi brillar amyloid from plaques and cerebral vessels, seemed to be temporally and regionally associated with vasogenic oedema and microhaemorrhage. A report in a small number of patients treated with gantenerumab, a conformationally specifi c monoclonal antibody with high affi nity for fi brillar forms of amyloid β, also provides evidence of reduced amyloid burden on ¹¹C PiB PET imaging in two patients who developed ARIA-E. 4 ARIA might also be related to clearance of amyloid from parenchymal plaques with a transient increase in vascular or peri vascular amyloid burden (fi gure 5C) 20, 21 or infl ammation. 22 Mobilisation of parenchymal β amyloid to perivascular drainage pathways that are impaired could also cause a transient paradoxical increase in vascular β amyloid after anti-β-amyloid immunotherapy (fi gure 5C).
However, similar to transgenic animals, [23] [24] [25] eventual normalisation of cerebral blood vessel integrity in people might also be possible (fi gure 5D). In post-mortem studies of patients included in an earlier active amyloid immunisation trial (AN1792), 20, 26 two participants had an almost complete absence of cerebral amyloid angiopathy, and they were among those who were followed up for the longest period (approximately 5 years). The fi nding that most ARIA-E occurred within the fi rst few doses could also support the hypothesis that vascular remodelling after amyloid clearance might reduce the risk of ARIA over time.
ARIA-E seems to rarely occur spontaneously; one case was identifi ed in the placebo group of study 201 and two cases were noted at screening. A report noted two spontaneous ARIA-E cases in more than 3000 patients screened for Alzheimer's disease clinical trials of semagacestat and solaneuzumab. 27 In view of reports of similar ARIA fi ndings in patients with cerebral amyloid angiopathy, 13, 14 it is possible that some of these spontaneous ARIA-E cases are patients with Alzheimer's disease who also have cerebral amyloid angiopathy.
Several potential limitations to our study should be noted. The MRI review was retrospective, and the results might have been diff erent if scans had been read prospectively, without access to other scans for
Panel: Research in context
Systematic review
We searched PubMed for articles published in English between Jan 1, 1980, and Dec 1, 2011, with the search terms "vasogenic edema", "amyloid-related imaging abnormalities (ARIA)", and "Alzheimer's disease." This search yielded three reports from the bapineuzumab phase 1 and 2 trials; one report of another monoclonal antibody, gantenerumab; one report of ARIA detected in screening cohorts for Alzheimer's disease clinical trials; and several review articles of drug development. A workgroup report 5 also cites abstracts for other classes of amyloid-modifying agents, but these data have not yet been published. Because ARIA in Alzheimer's disease clinical trials are a new concept, we broadened our search to include imaging reports from cerebral amyloid angiopathy cases that also seemed relevant to our fi ndings.
Interpretation
Our study is the fi rst systematic study of ARIA associated with amyloid-modifying therapies; particularly, abnormalities related to magnetic resonance signal alterations thought to be vasogenic oedema or sulcal eff usions (ARIA-E). We identifi ed numerous ARIA-E cases that were initially missed in the reported studies of bapineuzumab. Additionally, by combining cases across two phase 2 studies and an extension study, we could examine risk factors for development of ARIA-E. The increased risk of ARIA-E with presence of more APOE ε4 alleles, as well as previous case reports of similar abnormalities occurring spontaneously in cerebral amyloid angiopathy, suggests a potential relation with vascular amyloid burden. The increased risk of ARIA with a high bapineuzumab dose, the fi ndings from a case with PET amyloid imaging, and a report in a small number of patients treated with another monoclonal antibody suggest a possible relation of ARIA-E with amyloid β clearance. Our fi ndings have important implications for elucidation of the mechanisms underlying ARIA and warrant the close monitoring of ARIA in the development of anti-amyloid therapies for Alzheimer's disease.
comparison. The main aim of having two neuroradiologists to assess the scans was to increase the likelihood of detection of any potential MRI fi ndings consistent with ARIA; therefore, we did not provide extensive training to enhance inter-reader reliability. Nevertheless, the inter-reader reliability was high. Because we asked the readers to then discuss any cases with discrepant reads, we were not able to assess intra-rater reliability. A more detailed rating scale for both ARIA-E and ARIA-H is being developed, and will be used in future studies with the phase 3 data. We did not fi nd evidence of associated clinical symptoms in most ARIA cases, but subtle symptoms could have been missed in patients with mild to moderate dementia. Although this study includes the largest collection of ARIA cases related to treatment to date (panel), because of the small numbers of participants, we cannot defi nitively explore all potential risk factors, which will require further study in larger trials.
Our results suggest that ARIA consists of a spectrum of imaging fi ndings with variable clinical correlates during the trials, including a substantial number of cases that went undetected and were asymptomatic despite continued treatment. The frequent co-occurrence of ARIA-E and ARIA-H suggests that they share a common pathophysiological mechanism, which might be related to transient increases in vascular permeability. The increased risk of ARIA in APOE ε4 carriers further supports a key role for vascular amyloid, whereas the relation with bapineuzumab dose and the ¹¹C PiB PET amyloid fi ndings suggest that ARIA could be related to amyloid clearance. Ongoing studies with bapineuzumab and other potential amyloid-modifying therapies should provide further insight into the long-term implications of these abnormalities.
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